%0 Journal Article
%A Degerli, Esra
%A El-Marouk, Karim
%A Käsmann, Lukas
%A Khaltar, Khulangaa
%A Mansoorian, Sina
%A Richlitzki, Cedric
%A Kauffmann-Guerrero, Diego
%A Tufman, Amanda
%A Reinmuth, Niels
%A Duell, Thomas
%A Schmidt-Hegemann, Nina-Sophie
%A Manapov, Farkhad
%A Belka, Claus
%A Eze, Chukwuka
%T Empiric stereotactic body radiotherapy for presumed early-stage lung cancer : Pulmonary function changes, treatment-related toxicity and survival outcome.
%J Strahlentherapie und Onkologie
%V nn
%@ 0179-7158
%C Heidelberg
%I Springer Medizin
%M DKFZ-2025-01622
%P nn
%D 2025
%Z epub
%X Due to demographic shifts, the population is aging, and patients are experiencing more comorbidities. Stereotactic body radiotherapy (SBRT) offers high rates of local control for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). However, obtaining histopathological confirmation can be challenging due to severe comorbidities, small tumors, or unfavorable anatomical locations.Between 2011 and 2022, we retrospectively analyzed a cohort of patients who underwent lung SBRT for presumed early-stage NSCLC at our institution. Out of 486 consecutive patients treated during this period, 56 patients (11.5
%K Lung function (Other)
%K Lung neoplasms (Other)
%K Pathologic confirmation (Other)
%K Radiographic (Other)
%K Stereotactic ablative radiotherapy (SABR) (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40760181
%R 10.1007/s00066-025-02434-8
%U https://inrepo02.dkfz.de/record/303373